RESULT: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (clinicaltrials.gov) - Jul 9, 2026 - P2 | N=84 | Recruiting | Sponsor: Sanofi | -> Recruiting
Enrollment open • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Lupus Nephritis
|